192 related articles for article (PubMed ID: 16001164)
1. Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro.
Ren SP; Wu CT; Huang WR; Lu ZZ; Jia XX; Wang L; Lao MF; Wang LS
Cancer Immunol Immunother; 2006 Apr; 55(4):375-85. PubMed ID: 16001164
[TBL] [Abstract][Full Text] [Related]
2. Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma.
Wen XY; Mandelbaum S; Li ZH; Hitt M; Graham FL; Hawley TS; Hawley RG; Stewart AK
Cancer Gene Ther; 2001 May; 8(5):361-70. PubMed ID: 11477456
[TBL] [Abstract][Full Text] [Related]
3. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer.
Kim SH; Carew JF; Kooby DA; Shields J; Entwisle C; Patel S; Shah JP; Fong Y
Cancer Gene Ther; 2000 Sep; 7(9):1279-85. PubMed ID: 11023201
[TBL] [Abstract][Full Text] [Related]
4. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
[TBL] [Abstract][Full Text] [Related]
5. Growth suppression and immunogenicity enhancement of Hep-2 or primary laryngeal cancer cells by adenovirus-mediated co-transfer of human wild-type p53, granulocyte-macrophage colony-stimulating factor and B7-1 genes.
Qiu ZH; Wu CT; Lao MF; Pan LZ; Li YM
Cancer Lett; 2002 Aug; 182(2):147-54. PubMed ID: 12048160
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
7. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells.
Tarte K; Zhang XG; Legouffe E; Hertog C; Mehtali M; Rossi JF; Klein B
J Immunol; 1999 Jul; 163(1):514-24. PubMed ID: 10384156
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus mediated transfer of p53, GM-CSF and B7-1 suppresses growth and enhances immunogenicity of glioma cells.
Pan D; Wei X; Liu M; Feng S; Tian X; Feng X; Zhang X
Neurol Res; 2010 Jun; 32(5):502-9. PubMed ID: 19589203
[TBL] [Abstract][Full Text] [Related]
9. Co-transfer of human wild-type p53 and granulocyte-macrophage colony-stimulating factor genes via recombinant adenovirus induces apoptosis and enhances immunogenicity in laryngeal cancer cells.
Qiu Z; Lao M; Wu C
Cancer Lett; 2001 Jun; 167(1):25-32. PubMed ID: 11323095
[TBL] [Abstract][Full Text] [Related]
10. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
Xiang J; Chen Y; Moyana T
Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
[TBL] [Abstract][Full Text] [Related]
11. Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer.
Diaz RM; Todryk S; Chong H; Hart IR; Sikora K; Dorudi S; Vile RG
Gene Ther; 1998 Jul; 5(7):869-79. PubMed ID: 9813657
[TBL] [Abstract][Full Text] [Related]
12. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.
Levitsky HI; Montgomery J; Ahmadzadeh M; Staveley-O'Carroll K; Guarnieri F; Longo DL; Kwak LW
J Immunol; 1996 May; 156(10):3858-65. PubMed ID: 8621924
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor in a combination gene therapy strategy for head and neck cancer.
Day KV; Li D; Liu S; Guo M; O'Malley BW
Laryngoscope; 2001 May; 111(5):801-6. PubMed ID: 11368071
[TBL] [Abstract][Full Text] [Related]
14. Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells.
Dessureault S; Graham FL; Gallinger S
Cancer Gene Ther; 1999; 6(3):195-208. PubMed ID: 10359205
[TBL] [Abstract][Full Text] [Related]
15. Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response.
Wendtner CM; Nolte A; Mangold E; Buhmann R; Maass G; Chiorini JA; Winnacker EL; Emmerich B; Kotin RM; Hallek M
Gene Ther; 1997 Jul; 4(7):726-35. PubMed ID: 9282174
[TBL] [Abstract][Full Text] [Related]
16. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2.
Mogi S; Ebata T; Setoguchi Y; Fujime M; Heike Y; Kohsaka T; Yagita H; Okumura K; Azuma M
Clin Cancer Res; 1998 Mar; 4(3):713-20. PubMed ID: 9533541
[TBL] [Abstract][Full Text] [Related]
17. The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor.
Mukherjee S; Nelson D; Loh S; van Bruggen I; Palmer LJ; Leong C; Garlepp MJ; Robinson BW
Cancer Gene Ther; 2001 Aug; 8(8):580-8. PubMed ID: 11571536
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
[TBL] [Abstract][Full Text] [Related]
19. Genetically modified myeloma cell vaccine inducing antitumor immune response in vivo.
Ren SP; Wang LS; Guo Q; Wang H; Jia XX; Xu J; Wang HX; Wu CT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):54-60. PubMed ID: 16584592
[TBL] [Abstract][Full Text] [Related]
20. Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity.
Chong H; Todryk S; Hutchinson G; Hart IR; Vile RG
Gene Ther; 1998 Feb; 5(2):223-32. PubMed ID: 9578842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
